"myk-461 capsules
Sponsors
Myokardia Inc., Bristol-Myers Squibb Services Unlimited Company
Conditions
Symptomatic Obstructive Hypertrophic Cardiomyopathy
Phase 3
MEMENTO-A Phase 3b/4 Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to assess the impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging (CMR)
CompletedCTIS2022-502316-36-00
End: 2024-03-15Target: 105Updated: 2024-02-12
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (age 12 years to < 18 years) with Symptomatic Obstructive Hypertrophic Cardiomyopathy (SCOUT-HCM)
Active, not recruitingCTIS2023-505650-17-00
Start: 2024-08-27Target: 11Updated: 2025-11-07